Copyright
©The Author(s) 2021.
World J Gastrointest Surg. Sep 27, 2021; 13(9): 1000-1011
Published online Sep 27, 2021. doi: 10.4240/wjgs.v13.i9.1000
Published online Sep 27, 2021. doi: 10.4240/wjgs.v13.i9.1000
Table 2 Sites of initial recurrence according to the status of adjuvant chemotherapy
| Variables | ACTx (n = 413) | No ACTx (n = 107) | P value | |
| Recurrence, n (%) | 43 (10.4) | 8 (7.4) | ||
| Type of recurrence, n (%) | 0.009 | |||
| Local recurrence | 3 (0.7) | 4 (3.7) | ||
| Distant metastasis | 40 (9.7) | 4 (3.7) | ||
| Sites of distant metastasis1, n (%) | ||||
| Liver | 8 (20) | 1 (12.5) | ||
| Lung | 23 (57.5) | 2 (25) | ||
| Distant lymph nodes | 6 (15) | 1 (12.5) | ||
| Bone | 4 (10) | - | ||
| Brain | 1 (2.5) | - | ||
| Ovary | 1 (2.5) | - | ||
- Citation: Jeon YW, Park IJ, Kim JE, Park JH, Lim SB, Kim CW, Yoon YS, Lee JL, Yu CS, Kim JC. Evaluating the benefit of adjuvant chemotherapy in patients with ypT0–1 rectal cancer treated with preoperative chemoradiotherapy. World J Gastrointest Surg 2021; 13(9): 1000-1011
- URL: https://www.wjgnet.com/1948-9366/full/v13/i9/1000.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v13.i9.1000